Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Circulating Tumor Cells are Associated with Bone Metastasis of Lung Cancer

  • Cheng, Min (Department of Radiology, China-Japan Union Hospital, Jilin University) ;
  • Liu, Lin (Department of Radiology, China-Japan Union Hospital, Jilin University) ;
  • Yang, Hai-Shan (Department of Radiology, China-Japan Union Hospital, Jilin University) ;
  • Liu, Gui-Feng (Department of Radiology, China-Japan Union Hospital, Jilin University)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer (LC) is the leading cause of cancer mortality worldwide, predominantly due to the difficulty of early diagnosis and its high metastatic potential. Recently, increasing evidence suggests that circulating tumour cells (CTCs) are responsible for cancer metastatic relapse, and CTCs have attracted interest in cancer metastasis detection and quantification. In present study, we collected blood samples from 67 patients with bone metastasis, and 30 patients without such metastasis, and searched for CTCs. Then the association of CTC numbers with bone metastasis and other clinico-pothological variants was analyzed. Results demonstrated that when 5 or 1 was taken as a threshhold for the CTC number, there were significantly higher positivity of CTCs in the bone metastasis group than in the non-metastasis group. While the increase in CTC number was not significantly associated with any other clinicopathological factor, including age, gender, pathological type, intrapulmonary metastasis and lymph node metastasis, the CTC number in patients with positivity of the last above mentioned variants was obviously higher than in patients with negativity of the two variants. Taken together, the CTC number appears to be significantly associated with the bone metastasis from lung cancer.

Keywords

References

  1. Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA (2009). Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol, 4, 251-9. https://doi.org/10.1097/JTO.0b013e31819518fc
  2. Brown JE, Cook RJ, Major P, et al. (2005). Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst, 97, 59-69. https://doi.org/10.1093/jnci/dji002
  3. Carney DN (2002). Lung cancer-time to move on from chemotherapy. N Engl J Med, 346, 126-8. https://doi.org/10.1056/NEJM200201103460211
  4. Chute JP, Chen T, Feigal E, et al. (1999). Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol, 17, 1794-801.
  5. Cristofanilli M (2014). Circulating tumour cells: telling the truth about metastasis. Lancet Oncol, 15, 365-6. https://doi.org/10.1016/S1470-2045(14)70091-9
  6. Cristofanilli M, Budd GT, Ellis MJ, et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 351, 781-91. https://doi.org/10.1056/NEJMoa040766
  7. Currie GP, Kennedy AM, Denison AR (2009). Tools used in the diagnosis and staging of lung cancer: what's old and what's new? QJM, 102, 443-8. https://doi.org/10.1093/qjmed/hcp038
  8. Fidler IJ (1978). Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res, 38, 2651-60.
  9. Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
  10. Gorges TM, Tinhofer I, Drosch M, et al (2012). Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer, 12, 178. https://doi.org/10.1186/1471-2407-12-178
  11. Gregory DL, Hicks RJ, Hogg A, et al (2012). Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med, 53, 1007-15. https://doi.org/10.2967/jnumed.111.099713
  12. Grover PK, Cummins AG, Price TJ, et al (2014). Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol, 25, 1506-16 https://doi.org/10.1093/annonc/mdu018
  13. Hamilton W, Sharp D (2004). Diagnosis of lung cancer in primary care: a structured review. Fam Pract, 21, 605-11. https://doi.org/10.1093/fampra/cmh605
  14. Herbst RS, Heymach JV, Lippman SM (2008). Lung cancer. N Engl J Med, 359, 1367-80. https://doi.org/10.1056/NEJMra0802714
  15. Hiltermann TJ, Pore MM, van den Berg A, et al (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol, 23, 2937-42. https://doi.org/10.1093/annonc/mds138
  16. Hou JM, Krebs M, Ward T, et al (2011). Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol, 178, 989-96. https://doi.org/10.1016/j.ajpath.2010.12.003
  17. Isobe K, Hata Y, Kobayashi K, et al (2012). Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res, 32, 3339-44.
  18. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  19. Krebs MG, Hou JM, Ward TH, et al (2010). Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol, 2, 351-65. https://doi.org/10.1177/1758834010378414
  20. Lee JW, Lee SM, Lee HS, et al (2012). Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer. Ann Nucl Med, 26, 627-33. https://doi.org/10.1007/s12149-012-0622-3
  21. Ma XL, Xiao ZL, Liu L, et al (2012). Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev, 13, 1137-44. https://doi.org/10.7314/APJCP.2012.13.4.1137
  22. Mego M, De Giorgi U, Broglio K, et al (2009). Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer, 101, 1813-6. https://doi.org/10.1038/sj.bjc.6605413
  23. Mulshine JL, Smith RA (2002). Lung cancer. 2: screening and early diagnosis of lung cancer. Thorax, 57, 1071-8. https://doi.org/10.1136/thorax.57.12.1071
  24. Ni X, Zhuo M, Su Z, et al. (2013). Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA, 110, 21083-8. https://doi.org/10.1073/pnas.1320659110
  25. O'Flaherty JD, Gray S, Richard D, et al (2012). Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer, 76, 19-25. https://doi.org/10.1016/j.lungcan.2011.10.018
  26. Pierga JY, Bidard FC, Cropet C, et al (2013). Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Ann Oncol, 24, 2999-3004. https://doi.org/10.1093/annonc/mdt348
  27. Portilla-Quattrociocchi H, Banzo I, Martinez-Rodriguez I, et al. (2011). (Evaluation of bone scintigraphy and (18) F-FDG PET/CT in bone metastases of lung cancer patients). Rev Esp Med Nucl, 30, 2-7. https://doi.org/10.1016/j.remn.2010.10.005
  28. Riethdorf S, Wikman H, Pantel K (2008). Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer, 123, 1991-2006. https://doi.org/10.1002/ijc.23825
  29. Schmidt GP, Reiser MF, Baur-Melnyk A (2009). Wholebody MRI for the staging and follow-up of patients with metastasis. Eur J Radiol, 70, 393-400. https://doi.org/10.1016/j.ejrad.2009.03.045
  30. Shapley M, Mansell G, Jordan JL, Jordan KP (2010). Positive predictive values of >/=5% in primary care for cancer: systematic review. Br J Gen Pract, 60, 366-77. https://doi.org/10.3399/bjgp10X515412
  31. Shiota M, Bishop JL, Nip KM, et al (2013). Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res, 73, 3109-19.
  32. Sone S, Yano S (2007). Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev, 26, 685-9. https://doi.org/10.1007/s10555-007-9081-z
  33. Stenbygaard LE, Sorensen JB, Larsen H, Dombernowsky P (1999). Metastatic pattern in non-resectable non-small cell lung cancer. Acta Oncol, 38, 993-8. https://doi.org/10.1080/028418699432248
  34. Stovold R, Blackhall F, Meredith S, et al (2012). Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer-J Iaslc, 76, 263-8. https://doi.org/10.1016/j.lungcan.2011.11.015
  35. Tarhan MO, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9. https://doi.org/10.7314/APJCP.2013.14.3.1725
  36. Tseng JY, Yang CY, Liang SC, et al (2014). Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin Cancer Res, 20, 2885-97. https://doi.org/10.1158/1078-0432.CCR-13-2162
  37. Turker I, Uyeturk U, Sonmez OU, et al (2013). Detection of circulating tumor cells in breast cancer patients: prognostic predictive role. Asian Pac J Cancer Prev, 14, 1601-7. https://doi.org/10.7314/APJCP.2013.14.3.1601
  38. Wang FB, Yang XQ, Yang S, et al (2011). A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients-a meta-analysis. Asian Pac J Cancer Prev, 12, 2629-35.
  39. Wang Y, van Klaveren RJ, van der Zaag-Loonen HJ, et al (2008). Effect of nodule characteristics on variability of semiautomated volume measurements in pulmonary nodules detected in a lung cancer screening program. Radiology, 248, 625-31. https://doi.org/10.1148/radiol.2482070957
  40. Wong MP (2012). Circulating tumor cells as lung cancer biomarkers. J Thorac Dis, 4, 631-4.

Cited by

  1. Steroidal Saponins from Paris polyphylla Suppress Adhesion, Migration and Invasion of Human Lung Cancer A549 Cells Via Down-Regulating MMP-2 and MMP-9 vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10911
  2. Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy vol.6, pp.1, 2016, https://doi.org/10.1038/srep31423
  3. Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3471-6
  4. Clinical significance of circulating tumor cells from lung cancer patients using microfluidic chip vol.18, pp.2, 2018, https://doi.org/10.1007/s10238-018-0485-6
  5. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours vol.120, pp.3, 2019, https://doi.org/10.1038/s41416-018-0367-4
  6. Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo vol.19, pp.1, 2019, https://doi.org/10.1186/s12935-019-0735-z